Ion Beam Applications : IBA signs contract to install a fully integrated X-ray irradiation solution in France
Industrial Solutions / 22.12.2022 Significant contract win... | December 22, 2022
Industrial Solutions Significant contract win for IBA's Industrial Solutions; first time the division has sold a complete irradiation solution Louvain-La-Neuve, Belgium, 22 December 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announced that it has signed a contract to install a fully integrated X-ray irradiation solution at a customer's new service center site in France. The solution includes an IBA Rhodotron®, a Beagle® process control system, a safety access system, an overhead conveyor for pallets and automated pallet storage. The value of the contract for IBA is estimated at around EUR 20 million and a downpayment has been received. This latest contract further highlights the significant growth of IBA's Industrial Solutions division, which has had a strong 2022 and recently passed the milestone of EUR 100 million order intake to date. The deal comes in the context of evolving industrial market dynamics, particularly sterilization, which has seen its growth rate increase from 7 to 10% annually. Currently around 90% of the sterilization industry relies on ethylene oxide and Gamma radiation, derived from Cobalt-60. Both modalities are facing issues in terms of supply pressures and shortages, with ethylene oxide also being impacted by toxicity issues. Market challenges with incumbent sterilization technology have highlighted the need for high-quality alternative solutions such as X-ray and electron beam sterilization. IBA is the only manufacturer able to offer both X-ray and electron beam sterilization via its Rhodotron®, which has the largest power range of any accelerator on the market. Avoiding the use of toxic chemicals and radioactive materials, IBA's solutions are also significantly safer for the environment than the current standard. Thomas Servais, Vice President of IBA Industrial Solutions, commented: "This new contract underlines the continued growth of our sterilization solutions business, with order volumes up strongly in 2022. There is a clear opportunity for the future growth of IBA Industrial within the global sterilization landscape as we capitalize on the growth of the market and the need for an alternative, environmentally conscious solution to address the increasing demand." *** About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,800 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: URL  Data Bridge market research, 'Global Medical Device Sterilization Market - Industry Trends and Forecast to 2029' [link] Attachments Original Link Original Document Permalink
Disclaimer IBA - Ion Beam Applications SA published this content on 22 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 December 2022 05:51:04 UTC.
Sales 2022 346 M 367 M 367 M Net income 2022 12,3 M 13,1 M 13,1 M Net cash 2022 118 M 125 M 125 M P/E ratio 2022 35,7x Yield 2022 1,33% Capitalization 437 M 464 M 464 M EV / Sales 2022 0,92x EV / Sales 2023 0,80x Nbr of Employees 1 668 Free-Float 69,8% Chart ION BEAM APPLICATIONS, SA
Duration : Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max. Period : Day Week
Short TermMid-TermLong TermTrendsBullishNeutralNeutral
Mean consensus HOLD Number of Analysts 1 Last Close Price 15,00 € Average target price 18,00 € Spread / Average Target 20,0%